[1] FERNANDEZ-SAINZ I, MEDINA G N, RAMIREZ-MEDINA E, et al. Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine[J]. Virology, 2017, 502:123-132.
[2] ARZT J, JULEFF N, ZHANG Z, et al. The pathogenesis of foot-and-mouth disease I:viral pathways in cattle[J]. Transbound Emerg Dis, 2011, 58(4):291-304.
[3] STENFELDT C, SEGUNDO F D S, SANTOS T, et al. The pathogenesis of foot-and-mouth disease in pigs[J]. Front Vet Sci, 2016, 3:41.
[4] 李正平. 山羊呼吸道相关淋巴组织及鼻腔吸收灭活病毒的形态学研究[D]. 南京:南京农业大学, 2011:35-41.
LI Z P. Morphology of the respiratory tract associated lymphoid tissue and nasal absorption of inactivated virus in goat[D]. Nanjing:Nanjing Agricultural University, 2011:35-41. (in Chinese)
[5] 李乙江, 杨晶晶, 牛自兵, 等. 黄牛呼吸道IgA分泌细胞和淋巴组织分布的研究[J]. 南京农业大学学报, 2017, 40(6):1100-1104.
LI Y J, YANG J J, NIU Z B, et al. Distribution of IgA secreting cells and lymphoid tissues in cattle respiratory tract[J]. Journal of Nanjing Agricultural University, 2017, 40(6):1100-1104. (in Chinese)
[6] 杨倩. 黏膜免疫及其疫苗设计[M]. 北京:科学出版社, 2016:24-289.
YANG Q. Mucosal immunization and vaccine strategies[M]. Beijing:Science Press, 2016:24-289. (in Chinese)
[7] 申育萌, 杨倩. 枯草芽胞杆菌芽孢对猪扁桃体内树突状细胞的影响[J]. 畜牧兽医学报, 2015, 64(5):849-854.
SHEN Y M, YANG Q. Effects of intranasal administration with Bacillus subtilis spores on the dendritic cells in porcine tonsils[J]. Acta Veterinaria et Zootechnica Sinica, 2015, 64(5):849-854. (in Chinese)
[8] CHALLA S, SZCZEPANEK S M, ROOD D, et al. Bacterial toxin fusion proteins elicit mucosal immunity against a foot-and-mouth disease virus antigen when administered intranasally to guinea pigs[J]. Adv Virol, 2011, 2011:713769.
[9] AMUGUNI H, TZIPORI S. Bacillus subtilis:a temperature resistant and needle free delivery system of immunogens[J]. Hum Vaccin Immunother, 2012, 8(7):979-986.
[10] MNIF I, GHRIBI D. Review lipopeptides biosurfactants:mean classes and new insights for industrial, biomedical, and environmental applications[J]. Biopolymers, 2015, 104(3):129-147.
[11] MOU C X, ZHU L Q, XING X P, et al. Immune responses induced by recombinant Bacillus subtilis expressing the spike protein of transmissible gastroenteritis virus in pigs[J]. Antiviral Res, 2016, 131:74-84.
[12] XU W W, LIU H F, WANG X Q, et al. Surfactin induces maturation of dendritic cells in vitro[J]. Biosci Rep, 2016, 36(5):e00387.
[13] TAKADA A, MATSUSHITA S, NINOMIYA A, et al. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice[J]. Vaccine, 2003, 21(23):3212-3218.
[14] GEERAEDTS F, BUNGENER L, POOL J, et al. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs[J]. Influenza Other Respir Viruses, 2008, 2(2):41-51.
[15] RENEGAR K B, SMALL P A Jr, BOYKINS L G, et al. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract[J]. J Immunol, 2004, 173(3):1978-1986.
[16] MUTO K, KAMEI N, YOSHIDA M, et al. Cell-penetrating peptide penetratin as a potential tool for developing effective nasal vaccination systems[J]. J Pharm Sci, 2016, 105(6):2014-2017.
[17] ESTES D M. Regulation of IgA responses in cattle, humans and mice[J]. Vet Immunol Immunopathol, 2010, 138(4):312-317.
[18] CUBILLOS C, DE LA TORRE B G, JAKAB A, et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide[J]. J Virol, 2008, 82(14):7223-7230.
[19] ALEJO D M, MORAES M P, LIAO X F, et al. An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine[J]. Vaccine, 2013, 31(18):2302-2309.
[20] ÇOKÇALSKAN C, ÖZYÖRVK F, GVRSOY R N, et al. Chitosan-based systems for intranasal immunization against foot-and-mouth disease[J]. Pharm Dev Technol, 2014, 19(2):181-188.
[21] XIE Y L, GAO P, LI Z Y. A recombinant adenovirus expressing P12A and 3C protein of the type O Foot-and-Mouth disease virus stimulates systemic and mucosal immune responses in mice[J]. Biomed Res Int, 2016, 2016:7849203.
[22] ZANVIT P, TICHOPÁD A, HAVLCKOV M, et al. Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A[J]. Immunol Lett, 2010, 134(1):26-34.
[23] COOPER A M, ROBERTS A D, RHOADES E R, et al. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection[J]. Immunology, 1995, 84(3):423-432.
[24] FLYNN J L, GOLDSTEIN M M, TRIEBOLD K J, et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection[J]. J Immunol, 1995, 155(5):2515-2524.
[25] WAKEHAM J, WANG J, MAGRAM J, et al. Lack of both types 1 and 2 cytokines, tissue inflammatory responses, and immune protection during pulmonary infection by Mycobacterium bovis Bacille Calmette-Guérin in IL-12-deficient mice[J]. J Immunol, 1998, 160(12):6101-6111.
[26] LYADOVA I V, VORDERMEIER H M, ERUSLANOV E B, et al. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs[J]. Clin Exp Immunol, 2001, 126(2):274-279.
[27] CLAPP B, YANG X H, THORNBURG T, et al. Nasal vaccination stimulates CD8+ T cells for potent protection against mucosal Brucella melitensis challenge[J]. Immunol Cell Biol, 2016, 94(5):496-508.
[28] ROSE-JOHN S, WAETZIG G H, SCHELLER J, et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches[J]. Expert Opin Ther Targets, 2007, 11(5):613-624. |